Moderna, Inc.
NASDAQ:MRNABiotechnology
+$2.48 today
- Market cap
- $79.63B
- Beta
- 1.03
- P/E (TTM)
- -7.9
- EPS (TTM)
- -$8.09
Volume 6.91M
Average 6.53M
MRNA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Moderna, Inc.NASDAQ: MRNA
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development declines year over year
Q3 FY2026 research & development of $583M fell 27.2% year over year, behind the -23.6% change in trailing-twelve-month research & development. Sequentially, it fell 10.4% from the prior quarter. Over 3 fiscal years it compounded at -1.7% a year.
Context
- Research & development amounted to 161.1% of revenue in FY2025, up 19.1 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -27.2% toward the trailing-twelve-month pace of -23.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 3.13B USD
- Year-over-year change
- -31.1%
- 4-year CAGR
- +12.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.13B | -31.1% |
| FY2024 | 2024-12-31 | 4.54B | -6.2% |
| FY2023 | 2023-12-31 | 4.85B | +47.0% |
| FY2022 | 2022-12-31 | 3.3B | +65.5% |
| FY2021 | 2021-12-31 | 1.99B | — |
Research & Development vs competitors
How MRNA compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -23.6% is the 8th highest of 10, against a peer median of -0.6%.
- Research & development amounts to 105.3% of revenue for MRNA, versus a peer median of 57.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $11.05B USD | +7.0% | -3.0% | 17.3% | |
| LTM Jun 2026 | £9.2B GBP | +31.8% | +11.1% | 27.7% | |
| LTM Sep 2026 | $2.66B USD | -23.6% | -1.7% | 105.3% | |
| LTM Jun 2026 | €2.18B EUR | -0.6% | +9.6% | 82.6% | |
| LTM Jun 2026 | $1.03B USD | +74.2% | +67.4% | — | |
| LTM Mar 2026 | $446.24M USD | -15.0% | -3.0% | 681.3% | |
| LTM Mar 2026 | $345.36M USD | -10.9% | -35.2% | 57.9% | |
| LTM Mar 2026 | $98.25M USD | -44.3% | -8.8% | 216.6% | |
| LTM Mar 2026 | €85.57M EUR | +12.6% | -6.7% | 54.7% | |
| LTM Mar 2026 | $51.51M USD | -27.2% | -33.9% | — | |
| Peer median (excluding MRNA) | — | -0.6% | -3.0% | 57.9% | |
Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 17.74B | 18.88B | 6.85B | 3.2B | 1.94B |
| Cost of Revenue | 2.62B | 5.42B | 4.69B | 1.46B | 868M |
| Gross Profit | 15.12B | 13.46B | 2.16B | 1.74B | 1.08B |
| Gross Margin | 85.2% | 71.3% | 31.5% | 54.2% | 55.3% |
| Research & Development | 1.99B | 3.3B | 4.85B | 4.54B | 3.13B |
| Selling, General & Admin | 567M | 1.13B | 1.55B | 1.17B | 1.02B |
| Operating Expenses | 1.82B | 4.04B | 6.39B | 5.68B | 4.15B |
| Depreciation & Amortization | 232M | 348M | 621M | 189M | 215M |
| EBITDA | 13.54B | 9.95B | (3.28B) | (3.39B) | (2.55B) |
| EBITDA Margin | 76.3% | 52.7% | -47.9% | -106.1% | -131.3% |
| Operating Income | 13.3B | 9.42B | (4.24B) | (3.95B) | (3.07B) |
| Operating Margin | 75.0% | 49.9% | -61.9% | -123.3% | -158.1% |
| Interest Income | 18M | 200M | 421M | 425M | 314M |
| Interest Expense | 18M | 29M | 38M | 24M | 10M |
| Other Income / Expenses | (11M) | 155M | 297M | 338M | 306M |
| Income Before Tax | 13.29B | 9.58B | (3.94B) | (3.61B) | (2.77B) |
| Pre-Tax Margin | 74.9% | 50.7% | -57.6% | -112.8% | -142.4% |
| Income Tax Expense | 1.08B | 1.21B | 772M | (46M) | 54M |
| Net Income | 12.2B | 8.36B | (4.71B) | (3.56B) | (2.82B) |
| Net Margin | 68.8% | 44.3% | -68.8% | -111.3% | -145.2% |
| EPS (Basic) | 30.31 | 21.26 | (12.34) | (9.27) | (7.26) |
| EPS (Diluted) | 28.29 | 20.10 | (12.34) | (9.27) | (7.26) |
| Weighted Avg Shares | 403M | 394M | 382M | 384M | 389M |
| Weighted Avg Shares (Diluted) | 431M | 416M | 382M | 384M | 389M |
Moderna, Inc.
NASDAQ:MRNA
Intrinsic Alpha fair value
Locked
Current Price
$196.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.